Evaluating Host and Viral Factors Among HIV Infected Former Commercial Blood Donors in Fuyang, Anhui Province, China

This study has been completed.
Sponsor:
Collaborator:
Comprehensive International Program of Research on AIDS
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:
NCT00346762
First received: June 29, 2006
Last updated: May 16, 2014
Last verified: May 2014
  Purpose

HIV infected former commercial blood donors (FBDs) in Fuyang, Anhui Province, China were infected with HIV from a common-source exposure to contaminated blood. The purpose of this study is to examine the role of host and viral factors in HIV disease progression in this unique HIV infected population.


Condition Intervention
HIV Infections
Behavioral: Education

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Host and Viral Factors in HIV-1-Infected Typical Progressors and Long-Term Survivors Among Former Blood Donors in Anhui Province, China

Resource links provided by NLM:


Further study details as provided by National Institute of Allergy and Infectious Diseases (NIAID):

Primary Outcome Measures:
  • Change in CD4 count [ Time Frame: At Month 3 ] [ Designated as safety issue: Yes ]
  • Progression of HIV-1 disease [ Time Frame: At Month 22 ] [ Designated as safety issue: Yes ]

Biospecimen Retention:   Samples With DNA

Whole blood and urine


Enrollment: 186
Study Start Date: September 2005
Study Completion Date: August 2012
Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
1
HIV infected former commercial blood donors (FBDs) in Fuyang, Anhui Province
Behavioral: Education
HIV prevention education and risk reduction counselig

Detailed Description:

The HIV epidemic in China has reached a phase of exponential growth. Among the infected are FBDs in rural communities, who became infected through contaminated blood collection equipment. In Fuyang, Anhui Province, China, unregulated commercial blood collection occurred from 1992 to 1995; during the last decade or so, some HIV infected FBDs have progressed to AIDS, while others are long-term nonprogressors, not requiring antiretroviral therapy (ART). Since the HIV infected participants in this study are predicted to have been infected by the same or related HIV strain because of their location and how they were infected, this is a unique population to study. It is hypothesized that host factors, such as host immunity and genetic background, are better predictors of disease progression than viral factors in this population. This study will enroll HIV-1 infected FBDs and age-matched HIV uninfected adults in Fuyang, Anhui Province, China.

There are two stages in this study. Stage I is a cross-sectional study and will last 3 months. Participants will be HIV-1 infected FBDs and age-matched HIV uninfected controls. There are two study visits in Stage I; there will be a 2-day screening/enrollment visit and a follow-up visit. On the first day of screening/enrollment, participants will be briefed about the study and will be asked to complete demographic and risk factor questionnaires; medical and medication history will be reviewed and a physical examination will also occur. All participants will receive HIV prevention education and risk reduction counseling; additionally, HIV uninfected participants will receive HIV pretest counseling. On the second day of screening, participants will return to the clinic for blood collection, and females will undergo a pregnancy test. All participants will return to the clinic to receive their laboratory results and post-test counseling at a follow-up visit occurring approximately 2 weeks after their screening/enrollment visit. Any participant with a CD4 count less than 200 cells/mm3 or meeting other China Comprehensive AIDS Response (CARES) treatment criteria will be referred for further evaluation and care. HIV infected FBD participants with a CD4 count of 200 cells/mm3 or more will be invited to enroll in Stage II.

Stage II is a longitudinal, prospective study and will last 19.5 months. Stage II will enroll eligible HIV infected participants from Stage I and if necessary, other eligible patients referred from China CARES. There will be at least five study visits; they will occur at a 2-day study screening/enrollment visit, a follow-up visit 2 weeks after screening/enrollment, and Months 6, 12, and 18. Screening/enrollment and follow-up visit procedures will be identical to those conducted in Stage I. Visits at Months 6, 12, and 18 will occur over 2-day periods. Medical and medication history will be reviewed and a physical examination will occur on the first day; participants will need to return to the clinic for blood collection on the second day. Participants will receive laboratory results and post-test counseling at the next scheduled study visit. Additional study visits may be required if a participant experiences any clinically significant condition during the study.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Community sample of HIV infected and uninfected blood donors

Criteria

Inclusion Criteria for Stage I HIV Infected FBDs:

  • Self-reported history of blood donation in 1995 or before
  • HIV-1 infected
  • ART naive
  • Willing to provide locator information
  • Willing to use acceptable forms of contraception

Inclusion Criteria for Stage I HIV Uninfected Controls:

  • HIV uninfected
  • Willing to provide locator information
  • Willing to undergo repeat HIV testing

Inclusion Criteria for Stage II:

  • Participant of Stage I OR enrolled directly from the ongoing China CARES program
  • Self-reported history of blood donation in 1995 or before
  • HIV-1 infected
  • CD4 count of 200 cells/mm³ or more
  • ART naive and willing to notify study staff prior to initiating any ART
  • Clinical Stage I or II by the World Health Organization (WHO) Staging System
  • Willing to adhere to the study follow-up schedule
  • Willing to provide locator information
  • Willing to use acceptable forms of contraception

Exclusion Criteria for All Participants:

  • Concomitant use of ART during the study
  • Pregnancy

Exclusion Criteria for Stage II:

  • Plan to leave study area for more than 6 months during the follow-up period
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00346762

Locations
China
Fuyang Prefecture Endemic Station, Anhui Province CIPRA CRS
Beijing, China, 100050
Sponsors and Collaborators
Comprehensive International Program of Research on AIDS
Investigators
Study Chair: Yiming Shao, MD, PhD National Center for AIDS/STD Control and Prevention (NCAIDS), Chinese Center for Disease Control and Prevention (China CDC)
Principal Investigator: Jianqing Xu, MD, PhD National Center for AIDS/STD Control and Prevention (NCAIDS), Chinese Center for Disease Control and Prevention (China CDC)
Principal Investigator: Hui Xing, MD, MS National Center for AIDS/STD Control and Prevention (NCAIDS), Chinese Center for Disease Control and Prevention (China CDC)
Principal Investigator: Yuhua Ruan, PhD National Center for AIDS/STD Control and Prevention (NCAIDS), Chinese Center for Disease Control and Prevention (China CDC)
Principal Investigator: Jianjun Wang, MPH Anhui Provincial Center for Disease Control and Prevention
  More Information

Additional Information:
Publications:
Responsible Party: National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier: NCT00346762     History of Changes
Other Study ID Numbers: CIPRA CH 003, CIPRA, Project 3, 10402
Study First Received: June 29, 2006
Last Updated: May 16, 2014
Health Authority: United States: Federal Government

Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
Former Plasma Donors
Commercial Plasma Donors
Long-Term Nonprogressors
Host Factors
Viral Factors
HIV

Additional relevant MeSH terms:
HIV Infections
Acquired Immunodeficiency Syndrome
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases

ClinicalTrials.gov processed this record on July 24, 2014